The number of drugs on the health insurance reimbursement list has reached its lowest point in four and a half years. Due to pricing revisions for generic drugs and regulations related to joint development, the introduction of new drugs is significantly reduced. The number of approvals has decreased by more than 70% compared to the figures from four years ago.

According to the Health Insurance Review and Assessment Service (HIRA) report on the 16th, the total number of drugs listed on the reimbursement listing as of January 1st was 22,889. This represents a decrease of 754 drugs compared to 23,643 drugs listed in January of the previous year.

Furthermore, the number of reimbursed